Prevention of Malaria in Long-term Travelers
Open Access
- 8 November 2006
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 296 (18) , 2234-2244
- https://doi.org/10.1001/jama.296.18.2234
Abstract
Review from JAMA — Prevention of Malaria in Long-term Travelers — ContextLong-term travelers, defined here as those traveling for periods of 6 months or longer, face particular challenges regarding malaria prevention. Current guidelines for malaria prevention primarily address prevention of Plasmodium falciparum infections in short-term travelers.ObjectivesTo examine the risk of malaria in long-term travelers, recent developments in personal protective measures, and the safety and tolerability of malaria chemoprophylaxis during long-term use and to consider prevention strategies including continuous chemoprophylaxis, stand-by emergency self-treatment, seasonal prophylaxis, and strategies to prevent primary infection and relapses from P vivax malaria.Evidence AcquisitionComprehensive search of scientific publications including MEDLINE via both OVID and PubMED for relevant studies and articles with a cutoff date of July 2006, using the search terms long-term travel and malaria prevention, long-term malaria chemoprophylaxis, and insect repellent and malaria. Additional references were obtained from searching the bibliographies of the selected articles, from dissertations, and from the proceedings of relevant conferences on travel medicine. There were no language restrictions.Evidence SynthesisLong-term travelers have a higher risk of malaria than short-term travelers. Long-term travelers underuse personal protective measures and adhere poorly to continuous chemoprophylaxis regimens. A number of strategies are used during long-term stays: discontinuation of chemoprophylaxis after the initial period, sequential regimens with different medications for chemoprophylaxis, stand-by emergency self-treatment, and seasonal chemoprophylaxis targeting high-incidence periods or locations. All strategies have advantages and drawbacks. Counterfeit drugs sold in countries endemic for malaria pose serious concern for long-term travelers who purchase their medications overseas. Vivax malaria causes significant illness in travelers, but relapses of vivax malaria are not prevented with the current first-line chemoprophylaxis regimens. Consensus guidelines are needed for prevention of malaria in long-term travelers.ConclusionsPrevention of malaria in long-term travelers is a complex issue and requires expert advice from travel medicine specialists. Recommendations for prevention of malaria in long-term travelers must be individualized.Keywords
This publication has 11 references indexed in Scilit:
- Counterfeit anti-infective drugsThe Lancet Infectious Diseases, 2006
- Manslaughter by Fake Artesunate in Asia—Will Africa Be Next?PLoS Medicine, 2006
- Malaria prophylaxis policy for travellers from Europe to the Indian Sub ContinentMalaria Journal, 2006
- Biting time of Anopheles darlingi in the Bolivian Amazon and implications for control of malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- New strategies for the prevention of malaria in travelersInfectious Disease Clinics of North America, 2005
- The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the DangersPLoS Medicine, 2005
- Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective studyBMJ, 2004
- Field evaluation of the efficacy and persistence of insect repellents DEET, IR3535, and KBR 3023 against Anopheles gambiae complex and other Afrotropical vector mosquitoesTransactions of the Royal Society of Tropical Medicine and Hygiene, 2004
- Delayed Onset of Malaria — Implications for Chemoprophylaxis in TravelersNew England Journal of Medicine, 2003
- Comparison of three antigen detection tests for diagnosis and follow-up of falciparum malaria in travellers returning to Berlin, GermanyZeitschrift Fur Parasitenkunde-Parasitology Research, 2003